CLSDQ (Clearside Biomedical) PB Ratio: (As of Jul. 06, 2026)


CLSDQ Clearside Biomedical Inc CLSDQ
49 GF Score
Price $0.13
GF Value $6.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), Clearside Biomedical's share price is $0.125. Clearside Biomedical's Book Value per Share for the quarter that ended in Sep. 2025 was $-10.31. Hence, Clearside Biomedical's PB Ratio of today is .

The historical rank and industry rank for Clearside Biomedical's PB Ratio or its related term are showing as below:

During the past 12 years, Clearside Biomedical's highest PB Ratio was 33.64. The lowest was 0.73. And the median was 4.44.

CLSDQ's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.99
* Ranked among companies with meaningful PB Ratio only.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Clearside Biomedical was -4.70% per year. The lowest was -55.80% per year. And the median was -26.45% per year.

Back to Basics: PB Ratio


Clearside Biomedical  (OTCPK:CLSDQ) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Clearside Biomedical PB Ratio Related Terms


Clearside Biomedical PB Ratio Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical PB Ratio Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.21 4.33 6.40 0.00 0.00

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLSDQ vs LYRA, EVFM, ATXI: PB Ratio Comparison

For the Biotechnology subindustry, Clearside Biomedical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's PB Ratio falls into.


CLSDQ
49GF Score
Clearside Biomedical Inc CLSDQ
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearside Biomedical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Clearside Biomedical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2025)
=0.125/-10.308
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • PB Ratio:
  • GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for CLSDQ

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$6.34
GF Value